Table 1 Baseline sociodemographic and clinical characteristics of patients included in the study before and after the propensity score matchingb
All COVID-19 patients | PS matched COVID-19 patients | |||||
|---|---|---|---|---|---|---|
Total | Non-exposed to OACe | Exposed to OAC | Total after PS matching | Non-exposed to OAC (matched) | Exposed to OAC | |
N (%) | 311,542 | 299,714 | 11,828 | 20,360 | 10,180 | 10,180 |
Male sex | 137,258 (44.1) | 131,466 (43.9) | 5792 (49.0) | 9748 (47.9) | 4869 (47.8) | 4879 (47.9) |
Age, mean (SD) | 49.3 (22.3) | 48.2 (21.8) | 79.3 (11.8) | 79.9 (12.3) | 80.6 (12.6) | 79.2 (12.0) |
Smoking habit | 120,632 (38.7) | 115,326 (38.5) | 5306 (44.9) | 9022 (44.3) | 4478 (44.0) | 4544 (44.6) |
BMI, mean (SD)a | 26.8 (6.3) | 26.6 (6.3) | 29.1 (5.6) | 28.7 (5.5) | 28.2 (5.3) | 29.2 (5.6) |
Obesitya | 86,182 (50.5) | 79,789 (49.6) | 3199 (33.4) | 10,172 (39.2) | 6973 (42.7) | 3199 (33.4) |
COVID-19 diagnosis | ||||||
Positive | 164,557 (52.8) | 158,958 (53.0) | 5599 (47.3) | 9456 (46.4) | 4941 (48.5) | 4515 (44.4) |
Possible | 146,985 (47.2) | 140,756 (47.0) | 6229 (52.7) | 10,904 (53.6) | 5239 (51.5) | 5665 (55.6) |
LTCF | 28,361 (9.1) | 25,221 (8.4) | 3140 (26.5) | 6524 (32.0) | 3657 (35.9) | 2867 (28.2) |
MEDEA | ||||||
Unknown | 84,225 (27.0) | 80,384 (26.8) | 3841 (32.5) | 6877 (33.8) | 3627 (35.6) | 3250 (31.9) |
Rural area | 57,121 (18.3) | 55,050 (18.4) | 2071 (17.5) | 3851 (18.9) | 2028 (19.9) | 1823 (17.9) |
Urban quintiles 1–3 | 138,373 (44.4) | 133,279 (44.5) | 5094 (43.0) | 8787 (43.2) | 4331 (42.5) | 4456 (43.8) |
Urban quintiles 4–5 | 88,944 (28.5) | 86,051 (28.75) | 2893 (24.4) | 4696 (23.1) | 2222 (21.8) | 2474 (24.3) |
Comorbiditiesc | ||||||
Chronic kidney disease | 19,242 (6.2) | 15,497 (5.2) | 3620 (30.6) | 6254 (30.7) | 3154 (31.0) | 3100 (30.5) |
Diabetes | 31,079 (10.0) | 27,198 (9.1) | 3883 (32.8) | 6539 (32.1) | 3259 (32.0) | 3280 (32.2) |
Hypertension | 77,413 (24.8) | 68,395 (22.8) | 8998 (76.1) | 15,689 (77.1) | 7956 (78.2) | 7733 (76.0) |
Heart failure | 9649 (3.1) | 5837 (1.9) | 3393 (28.7) | 5242 (25.7) | 2359 (23.2) | 2883 (28.3) |
Ischemic coronary disease | 10,261 (3.3) | 8246 (2.8) | 2044 (17.3) | 3187 (15.7) | 1466 (14.4) | 1721 (16.9) |
Respiratory disease | 79,060 (25.4) | 73,444 (24.5) | 4460 (37.7) | 7528 (37.0) | 3747 (36.8) | 3781 (37.1) |
Thromboembolism | 1994 (0.6) | 1229 (0.4) | 589 (5.0) | 616 (3.0) | 93 (0.9) | 523 (5.1) |
Concomitant Drugsd | ||||||
Antiplatelets | 22,137 (7.1) | 21,378 (7.1) | 759 (6.4) | 1417 (7.0) | 797 (7.8) | 620 (6.1) |
LMWH | 2841 (0.9) | 2414 (0.8) | 427 (3.6) | 755 (3.7) | 409 (4.0) | 346 (3.4) |
NSAID | 76,224 (24.5) | 71,008 (23.7) | 5223 (44.2) | 8841 (43.4) | 4317 (42.4) | 4524 (44.4) |
Systemic corticosteroids | 16,138 (5.2) | 14,873 (5.0) | 1267 (10.7) | 2180 (10.7) | 1088 (10.7) | 1092 (10.7) |